Understanding the inflammatory response to cardiac surgery

Surgeon

Volumn 6, Issue 3, 2008, Pages 162-171

  McGuinness, J ^a   Bouchier Hayes, D ^a   Redmond, J M ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Endothelium; Inflammation; Inflammatory mediator; Leucocyte; Preconditioning

Indexed keywords

EID: 45249114192     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1479-666X(08)80113-8     Document Type: Review

References (79)

1. Wan S et al. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996; 112(3): 806-11
2. Baufreton C, Kirsch M, Loisance DY. Measures to control blood activation during assisted circulation. Ann Thorac Surg 1998; 66(5): 1837-44
3. Gillinov AM et al. Complement and neutrophil activation during cardiopulmonary bypass: a study in the complement-deficient dog. Ann Thorac Surg 1994; 57(2): 345-52
4. te Velthuis H et al. Myocardial performance in elderly patients after cardiopulmonary bypass is suppressed by tumor necrosis factor. J Thorac Cardiovasc Surg 1995; 110(6): 1663-9
5. Bennett-Guerrero E et al. Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA 1997; 277(8): 646-50
6. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg 2001; 71(2): 745-54
7. Cremer J et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996; 61(6): 1714-20
8. Gessler P et al. Plasma levels of interleukin-8 and expression of interleukin-8 receptors on circulating neutrophils and monocytes after cardiopulmonary bypass in children. J Thorac Cardiovasc Surg 2033; 126(3): 718-25
9. Ryan T et al. Lactic acidosis after cardiac surgery is associated with polymorphisms in tumor necrosis factor and interleukin 10 genes. Ann Thorac Surg 2002; 73(6): 1905-9; discussion 1910-1
10. Tönz M et al. Acute lung injury during carciopulmonary bypass. Are the neutrophils responsible? Chest 1995; 108(6): 1551-6
11. Sinclair DG et al. The effect of cardiopulmonary bypass on intestinal and pulmonary endothelial permeability. Chest 1995; 108(3): 718-24
12. Ascione R, Caputo M, Angelini DG. Off-pump coronary artery bypass grafting: not a flash in the pan. Ann Thorac Surg 2003; 75(1): 306-13
13. Struber M et al. Human cytokine responses to coronary artery bypass grafting with and without cardiopulmonary bypass. Ann Thorac Surg 1999; 68(4): 1330-5
14. Wan S, LeClerc JL, Vincent JL. Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Ann Thorac Surg 1997; 63(1): 269-76
15. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998; 274(3 Pt 2): R577-95
16. Martinez-Pellus AE. Endogenous endotoxemia of intestinal origin during cardiopulmonary bypass. Role of type of flow and protective effect of selective digestive decontamination. Intensive Care Med 1997; 23(12): 1251-7
17. Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg 1997; 85(4): 766-82
18. Jansen NJ et al. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 1992; 54(4): 744-7; discussion 747-8
19. Grotz MR. Intestinal cytokine response after gut ischemia: role of gut barrier failure. Ann Surg 1999; 229(4): 478-86
20. Edmunds LH Jr. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1998; 66(5 Suppl): S12-6; discussion S25-8
21. Asimakopoulos G et al. Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg 1999; 68(3): 1107-15
22. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75(2): S715-20
23. Watarida S et al. A clinical study on the effects of pulsatile cardiopulmonary bypass on the blood endotoxin levels. J Thorac Cardiovasc Surg 1994; 108(4): 620-5
24. Kawahito K et al. Enhanced responsiveness of circulatory neutrophils after cardiopulmonary bypass: increased aggregability and superoxide producing capacity. Artif Organs 2000: 24(1): 37-42
25. Sawa Y et al. Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. J Thorac Cardiovasc Surg 1996; 111(1): 29-35
26. Partrick DA et al. Cardiopulmonary bypass renders patients at risk for multiple organ failure via early neutrophil priming and late neutrophil disability. J Surg Res 1999; 86(1): 42-9
27. Lotan D et al. Soluble P-selectin and the post-operative course following cardiopulmonary bypass in children. Paediatr Anaesth 2001; 11(3): 303-8
28. Eikemo H, Sellevold OF, Videm V. Markers for enclothelial activation during open heart surgery. Ann Thorac Surg 2004; 77(1): 214-19
29. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320(6): 365-76
30. Boyle EM Jr. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg 1997; 63(1): 277-84
31. Harris NR, Russell JM, Granger DN. Mediators of endotoxin-induced leukocyte adhesion in mesenteric postcapillary venules. Circ Shock 1994; 43(4): 155-60
32. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 1999; 68(5): 1905-12
33. Hayashi Y et al. P-selectin participates in cardiopulmonary bypass-induced inflammatory response in association with nitric oxide and peroxynitrite production. J Thorac Cardiovasc Surg 2000; 120(3): 558-65
34. Tedesco F et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185(9): 1619-27
35. Elliott MJ, Finn AH. Interaction between neutrophils and endothelium. Ann Thorac surg 1993; 56(6): 1503-8
36. Korthuis RJ, Granger DN. Reactive oxygen metabolites, neutrophils, and the pathogenesis of ischemic-tissue/reperfusion. Clin Cardiol 1993; 16(4 Suppl 1: 119-26
37. Li XS, Wang QD, Pernow J. Beneficial effects of the endothelin receptor antagonist bosentan on myocardial and endothelial injury following ischaemia/reperfusion in the rat. Eur J Pharmacol 1995; 283(1-3): 161-68
38. Morgan EN et al. Nuclear factor kappaB mediates a procoagulant response in monocytes during extra-corporeal circulation. J Thorac Cardiovasc Surg 2003; 125(1): 165-71
39. Chong AJ et al. Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury. Ann Thorac Surg 2003; 75(2): S649-55
40. o Abu-Omar Y et al. The role of microembolisation in cerebral injury as defined by functional magnetic resonance: imaging. Eur J Cardiothorac Surg 2004; 26(3): 586-91
41. Hauser GJ et al. HSP induction inhibits iNOS mRNA expression and attenuates hypotension in endotoxin-challenged rats. Am J Physiol 1996; 271(6 Pt 2): H2529-35
42. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997; 112(3): 676-92
43. Levin RL et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004; 77(2): 496-9
44. Beal AI, Cerra FB. Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. JAMA 1994; 271(3): 226-33
45. Sekido N et al. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against, interleukin-8. Nature 1993; 365(6447): 654-7
46. Boyle EM Jr et al. Inhibition of interleukin-8 blocks myocardial ischemia-reperfiusion injury. J Thorac Cardiovasc Surg 1998; 116(1): 114-21
47. Julier K et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft. surgery: a double-blinded, placebo-controlled, multi-center study. Anesthesiology 2003; 98(6): 1315-27
48. Richter JA et al. Drew-Anderson technique attenuates systemic inflammatory response, syndrome and improves respiratory function after coronary artery bypass grafting. Ann Thorac Surg 2000; 69(1): 77-83
49. Mathew JP et al. Lower endotoxin immunity predicts increased cognitive dysfunction in elderly patients after cardiac surgery. Stroke 2003; 34(2): 508-13
50. Landis RC, Haskard DO, Taylor KM. New antiinflammatory and platelet-preserving effects of aprotinin. Ann Thorac Surg 2001; 72(5): S1808-13
51. Yellon DM, Dana A. The preconditioning phenomenon: A tool for the scientist or a clinical reality? Circ Res 2000; 87(7): 543-50
52. Bolli R. The late Phase of preconditioning. Circ Res 2000; 87(11): 972-83
53. Yellon DM, Alkhulaifi Am, Pugsley WB. Preconditioning the human myocardium. Lancet 1993; 342(8866): 276-7
54. Perrault LP, Menasche P. Preconditioning: can nature's shield be raised against surgical ischemic-reperfusion injury? Ann Thorac Surg 1999. 68(5): 1988-94
55. Vaage J, Valen G. Preconditioning and cardiac surgery. Ann Thorac Surg 2003; 75(2): S709-14
56. Boyle EM Jr et al. Treating myocardial ischemia-reperfusion injuiry by targeting endothelial cell transcription. Ann Thorac Surg 1999; 69(5): 1949-53
57. Thanos, D, Maniatis T. NF-kappa B: a lesson in family values, Cell 1995; 80(4): 529-32
58. Read MA et al. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation. J Exp Med 1994; 179(2): 503-12
59. Haudek SB et al. Overexpression of cardiac I-kappaBalpha prevents endotoxin-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol 2001; 280(3): H962-8
60. Shames BD et al. LPS-Induced NF-kappaB activation and TNF-alpha release in human monocytes are protein tyrosine kinase dependent and protein kinase C independent. J Surg Res 1999; 83(1): 69-74
61. Wright G et al. Endotoxin stress-response in cardiomyocytes: NF-kappaB activation and tumor necrosis factor-alpha expression. Am J Physiol Heart Circ Physiol 2002; 282(3): H872-9
62. Meldrum DR et al. On-pump coronary artery bypass surgery activates human myocardial NF-kappaB and increases TNF-alpha in the heart. J Surg Res 2003; 112(2): 175-9
63. Shames BD et al. increased levels of myocardial IkappaB-alpha protein promote tolerance to endotoxin. Am J Physiol 1998; 275(3 Pt 2): H1084-91
64. Verrier ED et al. Terminal complement blockade with pexelizumab during coronary artery-bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 2004; 291(19): 2319-27
65. Abraham E et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273(12): 934-41
66. Cohen G et al. Intraoperative myocardial protection: current trends and future perspectives. Ann Thorac Surg 1999; 68(5): 1995-2001
67. Zaugg M et al. Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms. Br J Anaesth 2003; 91(4): 551-65
68. Delerive P et al. DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol Endocrinol 2002; 16(5): 1029-39
69. Chen LW et al. The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003; 9(5): 575-81
70. Morgan EN et al. An essential role for NF-kappaB in the cardioadaptive response to ischemia. Ann Thorac Surg 1999; 68(2): 377-82
71. Benjamin IJ, McMillan DR. Stress (heat shock) proteins: molecular chaperones in cardiovascular biology and disease. Circ Res 1998; 83(2): 117-32
72. Valen G. The basic biology of apoptosis and its implications for cardiac function and viability. Ann Thorac Surg 2003; 75(2): S656-60
73. Li G et al. Myocardial protection by remote preconditioning: the role of nuclear factor kappa-B p105 and inducible nitric oxide synthase. Eur J Cardiothorac Surg 2004; 26(5): 968-73
74. McCormick PH et al. Clinically applicable thermal preconditioning attenuates leukocyte-endothelial interactions. J Am Coll Surg 2003; 197(1): 71-8
75. Kharbanda RK et al. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation 2001; 103(12): 1624-30
76. Shimizu M et al. Lipopolysaccharide pretreatment attenuates myocardial infarct size: A possible mechanism involving heat shock protein 70-inhibitory kappaBalpha complex and attenuation of nuclear factor kappaB. J Thorac Cardiovasc Surg 2002; 124(5): 933-41
77. Bauer P et al. Endothelial expression of selectins during endotoxin preconditioning. Am J Physiol Regul Integr Comp Physiol 2000; 279(6): R2015-21
78. Hausenloy DJ et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 2007. 370(9587): 575-9
79. McGuinness J et al. Myocardial protection using an omega-3 fatty acid infusion: quantification and mechanism of action. J Thorac Cardiovasc Surg 2006. 132(1): 72-9.